The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 21, 2023

Filed:

Sep. 13, 2019
Applicant:

Zenith Epigenetics Ltd., Calgary, CA;

Inventors:

Eric Campeau, Calgary, CA;

Laura Tsujikawa, Calgary, CA;

Sanjay Lakhotia, Orinda, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/437 (2006.01); A61K 31/5025 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/437 (2013.01); A61K 31/5025 (2013.01); A61K 45/06 (2013.01);
Abstract

The invention provides methods for treating triple negative breast cancer (TNBC), by co-administration of a BET bromodomain inhibitor selected from 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (Compound I), 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-1H-imidazo[4,5-b]pyridin-2-amine, and pharmaceutically acceptable salts/co-crystals thereof, and a second therapeutic agent to a subject in need thereof. The second therapeutic agent can be a PARP inhibitor, such as, e.g., talazoparib, olaparib or veliparib.


Find Patent Forward Citations

Campeau, Eric. (2023). Combination therapy for the treatment of triple-negative breast cancer (U.S. Patent No. 11607405). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11607405

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…